Zocilurtatug pelitecan shows promising results as a DLL3-targeted therapy for small cell lung cancer, with high response rates and ongoing trials.

Combination therapy with cadonilimab, a first-in-class bispecific antibody targeting both PD-1 and CTLA-4, and chemotherapy offers encouraging antitumor activity and manageable safety as a first-line ...

MUD HCT is associated with better survival outcomes and fewer severe complications compared to haploidentical HCT in acute ...

Reclassified disease response criteria at 28 days of treatment for acute graft-vs-host disease (GVHD) improved prediction of 6-month nonrelapse mortality (NRM) compared with conventional criteria in ...